Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Next Previous
Search
Trial Profile

A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms T-TIME

    • Most Recent Events

    • 12 Jan 2021 Results of pre-specified secondary analysis assessing associations between TIMI flow grade, treatment groups and microvascular obstruction published in the Heart
    • 01 Jan 2019 Primary endpoint has not been met. (The amount of MVO (% of Left Ventricular (LV) mass) revealed by late (10 - 15 min) gadolinium contrast enhancement MRI 2 days post-MI.), as reported in an article published in the JAMA: the Journal of the American Medical Association
    • 01 Jan 2019 Results published in the JAMA: the Journal of the American Medical Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top